X4 Pharmaceuticals (XFOR)

• Market cap: $33.1M
• 1 day: -2.30%
• 5 days: -9.53%
• 1 month: -39.18%
• 3 months: -62.41%
• 6 months: -61.59%
• Year to date: -74.63%
• 1 year: -84.10%
• 5 years: -98.07%
• 10 years: -99.77%
• Sector: Healthcare
• Industry: Biotechnology

About: X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Employees: 143

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

310% more call options, than puts

Call options by funds: $550K | Put options by funds: $134K

9% more capital invested

Capital invested by funds: $67.3M [Q3] → $73.2M (+$5.92M) [Q4]

10% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 21

1.17% less ownership

Funds ownership: 59.7% [Q3] → 58.53% (-1.17%) [Q4]

8% less funds holding

Funds holding: 98 [Q3] → 90 (-8) [Q4]

29% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 21

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.50 686% upside
• Avg. target: $2.25 1,079% upside
• High target: $3 1,472% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 23% 1-year accuracy 44 / 192 met price target	686% upside $1.50	Buy Reiterated	27 Mar 2025
Cantor Fitzgerald Kristen Kluska 24% 1-year accuracy 24 / 101 met price target	1,472% upside $3	Overweight Reiterated	26 Mar 2025